Curanex Pharmaceuticals Inc Common Stock
CURX
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.23M
Close$
$3.26
24.4% downside
Current Fair Value
24.4% downsideOvervalued by 24.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.23 Million |
|---|---|
| Enterprise Value | $3.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.98 |
| Beta | -2.57 |
| Outstanding Shares | 1,418,240 |
Return
| Return on Equity | -218.65% |
|---|---|
| Return on Assets | -206.32% |
| Return on Invested Capital | -211.68% |
Valuation & Multiples
| P/E Ratio | -0.6 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 1.44 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.34 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.18%▲ 0.02% |
|---|---|
| Total Invested | $89,016▼ 46.88% |
| Investors Holding | 11▲ 3.00% |
ESG Score
No data
About Curanex Pharmaceuticals Inc Common Stock
CEO: Jun Liu Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas,...